1. Home
  2. Companies
  3. ATX
  4. Material Events

Amplia Therapeutics (ASX:ATX) — Material Events

ASX:ATX · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 13 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
Amplia’s Narmafotinib Shows Survival Gains and Manufacturing Scale-UpMedium
Amplia Therapeutics reports positive ACCENT trial results, GMP production milestone, CFO appointment, and $27.9M cash at March 2026 quarter end
28 Apr 2026 ·Quarterly Activities and Cash Flow Report ·85
Amplia Therapeutics Raises $27.6M Amid Promising Pancreatic Cancer Trial ResultsMedium
Amplia Therapeutics reports $4.18M half-year loss, raises $27.6M to advance promising pancreatic cancer drug trials
27 Nov 2025 ·Appendix 4D and Half Year Financial Report ·85
Amplia Therapeutics Advances Pancreatic Cancer Drug with Positive Trial Data and $27.5M RaiseMedium
Amplia Therapeutics advances pancreatic cancer drug narmafotinib with positive trial data and $27.5M capital raise
29 May 2026 ·Annual Report ·85
Amplia’s Pancreatic Cancer Drug Shows 35% Response Rate, FDA Backs Dose PlanMedium
Amplia Therapeutics reports strong clinical trial progress, FDA support, patent grant, and solid cash position
30 Jan 2026 ·Quarterly Activities and Cash Flow Report ·85
Amplia Therapeutics Advances Pancreatic Cancer Drug with New Trial and Patent WinMedium
Amplia Therapeutics reports encouraging narmafotinib trial progress, key patent allowance, and A$27.5M capital raise
29 Oct 2025 ·Quarterly Activities and Cash Flow Report ·85
Amplia Therapeutics Advances Pancreatic Cancer Trials with $27.5M BoostMedium
Amplia Therapeutics reports strong ACCENT trial results, new trial approvals, and $27.5M capital raise
31 July 2025 ·Quarterly Activities and Cash Flow Report ·85
Amplia Therapeutics Secures A$27.5M to Accelerate Cancer Drug TrialsHigh
Amplia Therapeutics raises A$27.5 million to advance cancer drug trials
23 July 2025 ·Capital Raising ·85
Amplia’s Narmafotinib Shows Promising Gains in Pancreatic Cancer TrialMedium
Amplia Therapeutics reports superior interim ACCENT trial data for narmafotinib in pancreatic cancer
6 Aug 2025 ·Clinical Trial Data Release ·85
Amplia Therapeutics Gains FDA Backing for Pivotal Pancreatic Cancer TrialMedium
Amplia Therapeutics Secures Positive FDA Feedback on Phase 2b/3 Pancreatic Cancer Trial
20 Nov 2025 ·ASX Release ·80
Amplia Therapeutics Advances Narmafotinib with Phase 2b Daily Dosing Trial in Pancreatic CancerMedium
Amplia Therapeutics launches Phase 2b trial of narmafotinib for pancreatic cancer with new daily dosing
19 May 2026 ·Clinical Trial Initiation ·80
Amplia Therapeutics Surpasses $2.5M SPP Target, Fuelling Key Cancer TrialsMedium
Amplia Therapeutics raises A$2.65M via Share Purchase Plan, advancing clinical trials
26 Aug 2025 ·Capital Raising ·75
Amplia Therapeutics Doses First Patient in Pivotal Pancreatic Cancer TrialMedium
Amplia Therapeutics initiates pancreatic cancer trial with first patient dosed
4 Sept 2025 ·Clinical Trial Update ·75
Amplia and ANZGOG Launch PRROSE Trial Targeting Resistant Ovarian CancerMedium
Amplia Therapeutics and ANZGOG launch ovarian cancer trial for narmafotinib
8 May 2026 ·Clinical Trial Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.